MS4A1 and B-cell chronic lymphocytic leukemia: Their results have proven that using the dual liposomes have higher effects regarding induction of apoptosis than using either anti-CD19 immunoliposome or anti-CD20 immunoliposome suggesting that this strategy can be favorable for personalized treatment of B-CLL and B-cell malignancies in general.